Objective. We sought to evaluate the efficacy and feasibility of superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy (hereafter RADPLAT) for head and neck squamous cell cancer (hereafter HNSCC) patients with retropharyngeal lymph node (hereafter RPLN) metastasis.
Study Design. Retrospective case series reviewSetting. University medical center in Japan Subjects and Methods. Ten HNSCC patients with RPLN metastasis treated by RADPLAT were analyzed.Results. The ascending pharyngeal artery was targeted for the treatment of RPLN metastasis in 9 patients. The median total dose of cisplatin was 26.6 mg/m2 (mean, 31.5 mg/m2; range, 11.7-87.9 mg/m2). In the remaining patient, the RPLN was supplied by the ascending palatine artery. As grade 3 and 4 adverse effects, leukopenia was observed in three, mucositis in four and nausea in one patient. No neurological complications were observed in any patients. Metastatic RPLNs were evaluated as a complete response in all patients. There was no recurrence of RPLN metastasis in any patients. Four patients remain alive without any evidence of disease and six patients died of disease. The 5-year overall survival rate was 50%.Conclusions. We have shown that superselective intra-arterial cisplatin infusion for RPLNs was a feasible and 2 effective approach for HNSCC patients with RPLN metastasis.
INTRODUCTIONRetropharyngeal lymph node (RPLN) metastasis is considered to be a significant predictor of poor prognosis for patients with head and neck squamous cell carcinomas (HNSCCs) [1,2]. RPLN dissection is relatively simple and takes only a few minutes when performed electively. On the other hand, gross involvement of the RPLNs by the tumor can make the operation difficult and, at times, not feasible [3].Recently, superselective intra-arterial chemotherapy in combination with concomitant radiotherapy (RADPLAT) has been performed for patients with locally advanced HNSCC and has been reported to result in a favorable outcome, preserving function and improving survival [4,5]. We considered RADPLAT to be applicable to the treatment of RPLN metastasis and, therefore, assessed the efficacy and feasibility of this non-surgical treatment for HNSCC patients with RPLN metastasis.
MATERIALS AND METHODSPatients. Two hundred thirty-five patients with untreated HNSCCs underwent RADPLAT in Hokkaido University Hospital, Japan between September 1999 and July 2012. In this study, we analyzed ten patients who 3 had RPLN metastasis. The primary tumor sites were the hypopharynx in six, the maxillary sinus in two, and the oropharynx in two patients. Eight patients were diagnosed with Stage IVA, one with Stage IVB, the remaining patient with stage III. Other detailed characteristics are shown in Table 1 Cisplatin infusion mainly targeted the primary tumor, RPLNs and sometimes metastatic lymph nodes. At the same time, sodium thiosulfate (20-24 g) was given intravenously to neutralize cisplatin toxicity [6]. All arterial catheterizations were accomplished transcutaneo...